Telephone sharing button Contact Us mailbox sharing button
arrow_left sharing button
arrow_right sharing button

Press Releases

WuXi XDC and Cidara Therapeutics Expand Collaboration to Advance Cidara’s Oncology DFC Program
Feb. 02, 2023
WuXi XDC and Cidara Therapeutics Expand Collaboration to Advance Cidara’s Oncology DFC Program
  • The Agreement builds upon the existing collaboration for CMC development and GMP manufacturing of Cidara’s CD388 drug-Fc conjugate (DFC) for influenza to now include the oncology program


SHANGHAI, China and SAN DIEGO, CA, February 2, 2023 – WuXi XDC (“XDC”), a leading global CRDMO company dedicated to end-to-end bioconjugates services, and Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced an expansion of their existing collaboration under which WuXi XDC will provide investigational new drug (IND)-enabling chemistry, manufacturing and controls (CMC) development services for Cidara’s oncology program.


Cidara’s lead oncology program targets CD73 in the adenosine pathway, which contributes to immune evasion in solid cancers by flooding the tumor microenvironment with adenosine, a potent immune cell suppressor. CD73 is highly expressed on a variety of tumor and stromal cells as well as immunosuppressive cell populations, such as regulatory T cells and myeloid-derived suppressor cells. Cidara’s lead CD73 DFC is designed to address the potency, efficacy, pharmacokinetic and safety limitations of small molecule and monoclonal antibody candidates targeting CD73.


“WuXi XDC has been an excellent development and manufacturing partner for our ongoing CD388 DFC influenza program, and we are excited to expand this relationship by combining WuXi XDC’s core competencies in bioconjugates manufacturing with our expertise in DFCs to advance the manufacturing of our first-in-class oncology program,” said Jeff Stein, Ph.D., president and CEO of Cidara Therapeutics.


Dr. Jimmy Li, CEO of WuXi XDC, added, “We’re thrilled to expand our strategic collaboration with Cidara to further develop new bioconjugates solutions. This expanded partnership is a strong testament to our industry-leading capabilities and expertise. We’re committed to building an innovation ecosystem for bioconjugates by offering global open-access technology platforms with premier quality standards to support our partners worldwide as they build their innovative ideas into transformative new treatments for patients.”


About Cloudbreak® DFCs


Cidara is developing a new generation of immunotherapeutic agents from its Cloudbreak platform that couple potent drugs to a human antibody fragment (Fc). These highly potent, long-acting drug-Fc conjugates (DFCs) are designed to inhibit specific disease targets while simultaneously engaging the immune system. In addition to its oncology program, Cidara is advancing its antiviral DFC CD388 through Phase 1 and Phase 2a clinical trials in partnership with Janssen for the universal prevention and treatment of influenza. Cidara is also advancing DFC programs to target other life-threatening viruses, such as SARS-CoV-2.


About Cidara Therapeutics


Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to drug-Fc conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform. Cidara is headquartered in San Diego, California. For more information, please visit


About WuXi XDC


WuXi XDC, a joint venture between WuXi Biologics and WuXi STA, provides end-to-end contract research, development and manufacturing of bioconjugates, including antibody drug conjugates (ADCs). The company’s services cover antibodies and other biologics, chemical payloads and linkers, as well as bioconjugated drug substance and drug product. WuXi XDC has been successful in bringing multiple ADC projects to the Investigational New Drug (IND) filing stage in 15 months or less, nearly cutting in half the traditional development timeline. As of September 30, 2022, WuXi XDC is supporting 270 integrated client projects, including 29 in post-IND and 8 in late-phase stage. For more information about WuXi XDC, please visit:


Cidara Contact



Patrick Bursey

LifeSci Communications

(203) 430-9545



Brian Ritchie

LifeSci Advisors

(212) 915-2578


WuXi Biologics Contact






You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?